Ultragenyx Pharmaceutical Inc.
RARE
$26.84
$0.542.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 413.00M | 680.00M | 425.25M | 487.59M | 494.44M |
| Total Receivables | 124.00M | 160.00M | 116.34M | 127.36M | 102.84M |
| Inventory | 55.00M | 52.00M | 52.20M | 46.50M | 46.03M |
| Prepaid Expenses | 57.00M | 46.00M | 39.59M | 49.31M | 47.37M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 8.00M | 13.00M | 9.83M | 9.04M | 8.48M |
| Total Current Assets | 657.00M | 951.00M | 643.21M | 719.79M | 699.16M |
|
|
|||||
| Total Current Assets | 657.00M | 951.00M | 643.21M | 719.79M | 699.16M |
| Net Property, Plant & Equipment | 239.00M | 267.00M | 249.96M | 255.76M | 260.91M |
| Long-term Investments | 44.00M | 44.00M | 44.41M | 44.41M | 44.41M |
| Goodwill | 44.00M | 44.00M | 44.41M | 44.41M | 44.41M |
| Total Other Intangibles | 174.00M | 176.00M | 172.94M | 174.73M | 176.52M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 61.00M | 37.00M | 57.86M | 60.12M | 62.37M |
| Total Assets | 1.30B | 1.53B | 1.19B | 1.31B | 1.31B |
|
|
|||||
| Total Accounts Payable | 42.00M | 31.00M | 40.57M | 34.24M | 47.45M |
| Total Accrued Expenses | 194.00M | 265.00M | 220.53M | 180.79M | 173.01M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 72.00M | 81.00M | 77.69M | 75.63M | 67.86M |
| Total Finance Division Other Current Liabilities | 17.00M | 7.00M | 1.24M | 2.58M | 3.35M |
| Total Other Current Liabilities | 17.00M | 7.00M | 1.24M | 2.58M | 3.35M |
| Total Current Liabilities | 325.00M | 384.00M | 340.02M | 293.24M | 291.67M |
|
|
|||||
| Total Current Liabilities | 325.00M | 384.00M | 340.02M | 293.24M | 291.67M |
| Long-Term Debt | 1.13B | 1.15B | 763.74M | 782.75M | 794.05M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | 24.00M | 21.69M | 24.53M | 27.79M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 72.00M | 50.00M | 48.84M | 47.46M | 47.18M |
| Total Liabilities | 1.53B | 1.61B | 1.17B | 1.15B | 1.16B |
|
|
|||||
| Common Stock & APIC | 4.48B | 4.45B | 4.41B | 4.37B | 4.25B |
| Retained Earnings | -4.72B | -4.53B | -4.40B | -4.22B | -4.11B |
| Treasury Stock & Other | 0.00 | 1.00M | 820.00K | -268.00K | -341.00K |
| Total Common Equity | -236.00M | -80.00M | 9.16M | 151.29M | 144.25M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | -236.00M | -80.00M | 9.16M | 151.29M | 144.25M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | 7.00M | 7.00M | 7.00M | 7.00M | 7.00M |
| Total Equity | -229.00M | -73.00M | 16.16M | 158.29M | 151.25M |
|
|
|||||